FATE news

Fate Therapeutics announced a $15 million CIRM grant for its Phase 2 lupus nephritis trial, advancing its FT819 off-the-shelf CAR T-cell therapy. The funding is intended to broaden access to this potentially curative treatment.

Fate Therapeutics Inc filed amendments to its Third Amended and Restated 2022 Stock Option and Incentive Plan to facilitate equity-based compensation for officers, employees, directors and consultants. The plan modification aligns employee interests with shareholder value creation through various aw…

Fate Therapeutics presented its corporate pipeline progress focusing on off-the-shelf cell therapy development with plans to commence Phase 2 studies. The advancement of novel CAR T-cell therapies represents potential clinical and commercial progress for the cell therapy company.